Soquelitinib

Phase 3

47%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Nov 2026~

CRVS⭐Phase 3Phase 3

Soquelitinib Phase 3 Results Expected

Soquelitinib • Peripheral T-Cell Lymphoma, Not Otherwise Specified

Drug Information

Target Indication

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Clinical Trial

Last updated: 12/4/2025

Developer

CRVS

Corvus Pharmaceuticals, Inc.